Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Disease × lortalamine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Recurrence 1 Prostatic Neoplasms 1 Neoplasms 1 Disease 1

Interventions

Dexamethasone 5 Magnetic Resonance Spectroscopy 4 Cyclophosphamide 4 Blood Specimen Collection 4 Surveys and Questionnaires 3 Prednisone 3 Melphalan 3 Lenalidomide 3 Biopsy, Fine-Needle 3 fluciclovine F-18 2 carfilzomib 2 Positron-Emission Tomography 2 Mammography 2 Injections 2 Immunohistochemistry 2 Gemcitabine 2 Cytarabine 2 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2 weifuchun 1 vistusertib 1 venetoclax 1 technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1 ricolinostat 1 pomalidomide 1 phosphoribosylformylglycinamidine synthetase 1 pembrolizumab 1 ofatumumab 1 obinutuzumab 1 lortalamine 1 irinotecan sucrosofate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡